1-(4-hydroxyphenyl)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid | 353263-80-6

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 1-(4-hydroxyphenyl)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid
• 英文别名: 1-(4-hydroxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-ium-3-carboxylate
• CAS: 353263-80-6
• 化学式: C₁₈H₁₆N₂O₃
• 分子量: 308.337
• InChiKey: OHWUOYUHWJMINH-UHFFFAOYSA-N

物化性质

• 沸点：
  612.4±55.0 °C(Predicted)
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  85.4
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-hydroxyphenyl)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid 在 sulfur 、 copper(l) chloride 、 N,N'-二异丙基碳二亚胺 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 10.0h， 生成
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE
  [FR] INHIBITEURS À PETITES MOLÉCULES DE L'UBIQUITINE LIGASE CRL4

  摘要：

  Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1 expression or activity for the treatment or prevention of cancer, DNA damage, or related conditions. In some aspects, the interaction between CUL4A and/or CUL4B and the beta-propeller B of DDB1 is disrupted with the compounds, compositions, or methods.

  公开号：

  WO2023173136A2
• 作为产物：
  描述：

  对羟基苯甲醛 、 DL-色氨酸 在 溶剂黄146 作用下， 以81 %的产率得到1-(4-hydroxyphenyl)-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF THE CRL4 UBIQUITIN LIGASE
  [FR] INHIBITEURS À PETITES MOLÉCULES DE L'UBIQUITINE LIGASE CRL4

  摘要：

  Compounds of formula (I), compounds of formula (II), and compounds of formula (III) are disclosed. Also disclosed are compounds, compositions, and methods to inhibit CUL4A expression or activity, CUL4B expression or activity, and/or DDB1 expression or activity for the treatment or prevention of cancer, DNA damage, or related conditions. In some aspects, the interaction between CUL4A and/or CUL4B and the beta-propeller B of DDB1 is disrupted with the compounds, compositions, or methods.

  公开号：

  WO2023173136A2

文献信息

• [EN] CARBOLINE AND BETACARBOLINE DERIVATIVES FOR USE AS HDAC ENZYME INHIBITORS<br/>[FR] DERIVES DE CARBOLINE ET DE BETACARBOLINE INHIBITEURS DE L'ENZYME HDAC
  申请人：CHROMA THERAPEUTICS LTD

  公开号：WO2004113336A1

  公开（公告）日：2004-12-29

  Compounds of formula (IA) and (IB) are inhibitors of histone deacetylase activity and useful for the treatment of, inter alia, cancers: wherein fused rings A1 and A2 are optionally substituted; linker radical R1 represents a radical of formula

  式（IA）和（IB）的化合物是组蛋白去乙酰化酶活性的抑制剂，用于治疗癌症等疾病：其中融合的环A1和A2可以选择性地被取代；连接基团R1代表一个公式的基团。
• COMPOUND HAVING STAT3 INHIBITORY ACTIVITY AND USE THEREOF
  申请人：CYTUS H&B CO., LTD.

  公开号：US20200354327A1

  公开（公告）日：2020-11-12

  The present invention relates to a compound exhibiting STAT3 inhibitory activity, or a pharmaceutically acceptable salt, solvate or hydrate of the same, and pharmaceutical uses of these. The compounds of the present invention efficiently inhibit the abnormal activity of STAT3 associated with various diseases and thus can be usefully utilized for the prevention and treatment of various STAT3-related diseases associated with cancer, autoimmune diseases, inflammatory diseases and the like.

  本发明涉及一种具有STAT3抑制活性的化合物，或其药学上可接受的盐、溶剂或水合物，以及这些化合物的药物用途。本发明的化合物有效地抑制了与各种疾病相关的STAT3异常活性，因此可用于预防和治疗与癌症、自身免疫性疾病、炎症性疾病等相关的各种STAT3相关疾病。
• Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo
  申请人：Wu Jialin

  公开号：US20090227619A1

  公开（公告）日：2009-09-10

  This invention relates to compounds of general formula (I), wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumour activity and lower nervous system toxicity by structurally modification of the parent structure of β-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumour medicines and medicines used in treatment of tumour diseases in combination of light or radiation therapy.

  本发明涉及一般式（I）的化合物，其中R1、R2、R3、R4和R5如规范中所定义；用于它们的制备的中间体，制备方法和使用。本发明通过在β-噻吩类似物的母体结构的1、2、3、7和9位进行结构修饰，产生具有增强抗肿瘤活性和较低神经系统毒性的新的harmine衍生物。本发明的化合物可以轻松高产制备。它们可以用于制造各种抗肿瘤药物和用于结合光或放射治疗治疗肿瘤疾病的药物。
• HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF
  申请人：Xinjiang Huashidan Pharmaceutical Research Co., Ltd.

  公开号：EP1634881B1

  公开（公告）日：2011-07-27
• US8772311B2
  申请人：——

  公开号：US8772311B2

  公开（公告）日：2014-07-08